Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?

Autor:	Sarit Assouline, Morgan L. McLemore, Leon Bernal-Mizrachi, Elliott F. Winton, Debra Saxe, Martha Arellano, Lisa Lima, Sharron Nault, Jorge E. Cortes, Keeran Sampat, Mourad Tighiouart, Hanna Jean Khoury
Rok vydání:	2011
Předmět:	Adult Male Cancer Research medicine.medical_specialty Time Factors Adolescent Fusion Proteins bcr-abl Philadelphia chromosome Gastroenterology Piperazines Myelogenous Young Adult hemic and lymphatic diseases Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans Oncogene Proteins v-abl Protein Kinase Inhibitors In Situ Hybridization Fluorescence Aged Aged 80 and over medicine.diagnostic_test Dose-Response Relationship Drug business.industry Myeloid leukemia Imatinib Hematology Middle Aged medicine.disease Prognosis Hematologic Diseases Haematopoiesis Leukemia Imatinib mesylate Pyrimidines Treatment Outcome Oncology Immunology Benzamides Proto-Oncogene Proteins c-bcr Imatinib Mesylate Female business medicine.drug Fluorescence in situ hybridization Follow-Up Studies
Zdroj:	Leukemialymphoma. 52(6)
ISSN:	1029-2403
Popis:	Imatinib (IM)-associated myelosuppression is rare in gastrointestinal stromal cell tumors (10%) but common in chronic myeloid leukemia (CML). Selective inhibition of predominantly Philadelphia chromosome (Ph+) driven hematopoiesis may explain myelosuppression in CML. In the absence of clinical methods to quantitate the Ph+/Ph- progenitor ratio, we hypothesized that the pre-IM percentage of BCR-ABL+ cells measured by fluorescence in situ hybridization (FISH) predicts for myelosuppression. FISH analyses performed within 30 days pre-IM 400 mg/day were analyzed in 89 patients with chronic phase CML at three institutions. Patients who developed grade ≥3 cytopenias had a higher percentage of positive FISH (90% vs. 83%; p = 0.02). Cytopenias lasted a median of 16 days, and all patients but one continued IM, achieved complete hematologic and cytogenetic remissions, and did not experience progression, with a follow-up of 61 months. In conclusion, IM-associated cytopenias are associated with a high pre-IM FISH, are reversible, and do not adversely affect outcomes.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c6d1ceccfe36c9d055866cb1e365fe https://pubmed.ncbi.nlm.nih.gov/21599589 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.